Exercise eases depression, and a brain growth factor may explain why

Exercise is one of the better-evidenced non-drug approaches to depression, yet the biological route by which it lifts mood has never been pinned down. Candidate pathways include inflammatory markers, neurotrophic factors such as BDNF, and compounds linked to neurotransmitter metabolism such as kynurenine. If specific blood markers move with training and track the improvement in symptoms, that would make the antidepressant effect of exercise easier to understand and, eventually, to target. This review set out to establish what exercise training does over time to circulating biomarkers in adults with major depressive disorder, and whether those changes relate to symptom change.

The authors screened seven databases for randomised controlled trials published up to February 2020 in which adults with major depressive disorder undertook exercise training. From 3865 records, 12 trials met the criteria, covering 757 participants with a mean age of 43.0 years, of whom 66.2% were women. Two reviewers screened studies independently, and results were pooled using random-effects models. A multivariate meta-regression then tested whether changes in circulating biomarkers were associated with changes in depressive symptoms across the trials.

Compared with control groups, exercise training produced a superior increase in circulating BDNF and in kynurenine, and a clear reduction in depressive symptoms. The meta-regression found that improvements in circulating BDNF, kynurenine and interleukin-6 were associated with decreases in depressive symptoms. Coverage of other candidate markers was thin: few trials reported markers such as TNF-α or IL-10, so the review could not say much about them. The included trials also failed to report medication use consistently, so results could not be separated by the antidepressants participants were taking.

The antidepressant effect of exercise is already widely reported; what this review adds is a biological account that fits it, with neurotrophic and inflammatory markers moving in step with mood. That link is correlational, drawn across a small set of trials, so it raises a hypothesis rather than confirming a mechanism. It also leaves open questions the trials could not answer: whether particular types, doses or durations of exercise matter more, how medication interacts with the effect, and whether the thinly reported markers play a role.

This is a reason to see the mood benefits of regular training as biologically grounded rather than a placebo or a distraction effect, at least in adults with diagnosed major depression. The symptom improvement in the pooled trials was substantial, and it travelled with measurable changes in the blood. None of this changes what training involves, and it says nothing about exercise replacing other treatment. It simply means that when movement helps a low mood, there is emerging evidence of real chemistry underneath.